Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Papp, Márta
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD	Active, not recruiting	3	806	Europe, Canada, Japan, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD	Pulmonary Disease, Chronic Obstructive	08/24	08/24
RESPONSE, NCT05743608: NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients	Recruiting	N/A	1000	Europe		Chiesi Hungary Ltd., Chiesi Slovenija, d.o.o., CHIESI Bulgaria Ltd., CHIESI CZ s.r.o.	COPD	06/24	08/24
Tóth, Tivadar
RESPONSE, NCT05743608: NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients	Recruiting	N/A	1000	Europe		Chiesi Hungary Ltd., Chiesi Slovenija, d.o.o., CHIESI Bulgaria Ltd., CHIESI CZ s.r.o.	COPD	06/24	08/24